Radioembolization in the Treatment of Neuroendocrine Tumors of the Pancreas
Abstract
Pancreatic neuroendocrine tumors (pNET) are a rare malignancy. Many patients will present with metastatic disease most commonly to the liver. Currently the standard of care for treatment of liver metastases from neuroendocrine tumors (NETs) is surgical resection. However, only few patients are candidates for surgical resection and require alternative options. Given the rarity of this disease; data regarding treatment options are minimal. In this paper, we will review data presented at the annual meeting of ASCO 2014 about the Survival following Y90 radioembolization for neuroendocrine tumor liver metastases (Abstract #e15166). This abstract shows evidence for survival benefit with the use of radioembolization in the treatment of metastatic neuroendocrine tumors to the liver.
Image: Tufts Medical Center. Boston, MA, USA
Downloads
References
Kuo JH, Lee JA, Chabot JA. Nonfunctional Pancreatic Neuroendocrine Tumors. Surg Clin North Am. 2014; 94(3): 689-708. [PMID:24857584]
Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, et al. Radioembolization of symptomatic,unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012; 35(2): 334-42. [PMID:21847708]
Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreaticendocrine tumors. Gastroenterology. 2008 Nov; 135(5): 1469-92. [PMID:18703061]
Gupta S. Intra-Arterial Liver-Directed Therapies for Neuroendocrine Hepatic Metastases. Semin Intervent Radiol. 2013 ; 30(1): 28-38. [PMC:3700796]
Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998; 83(11): 2293-301. [NBK:6993]
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005; 104(8): 1590-602. [PMID:16134179]
Kalinowski M, Dressler M, König A, El-Sheik M, Rinke A, Höffken H, Gress TM, et al. Selective internal radiotherapy with Yttrium-90microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009; 79(3): 137-42. [PMID:19307736]
Shaheen M, Hassanain M, Aljiffry M, Cabrera T, Chaudhury P, Simoneau E,Kongkaewpaisarn N, et al. Predictors of response to radio-embolization (TheraSphere®) treatmentof neuroendocrine liver metastasis. HPB (Oxford). 2012; 14(1): 60-6. [PMID:22151453]
Gruener J, Nowakowski FS, Fardanesh R, Amin V, Kim E, Fischman AM, Patel RS, et al. Survival following Y90 radioembolization for neuroendocrine tumor liver metastases: A retrospective, single-center analysis. J Clin Oncol 32, 2014 (suppl; abstr e15166).
Copyright (c) 2014 Preethi K John, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.